current
flu
epidem
caus
influenza
viru
first
appear
mexico
emerg
communic
human
diseas
late
march
rapidli
spread
throughout
world
april
due
rapid
transport
system
modern
time
epidem
affect
countri
less
month
http
cumul
number
confirm
new
case
reach
death
till
juli
averag
death
rate
peopl
infect
new
viru
although
death
rate
caus
new
viru
lower
avian
influenza
viru
last
epidem
latent
threat
unpredict
new
viru
much
infecti
human
importantli
popul
immun
viru
addit
would
usual
take
month
time
appropri
strain
identifi
first
dose
vaccin
becom
avail
influenza
pandem
includ
spanish
flu
trigger
avian
influenza
viru
humanavian
reassort
viru
acquir
abil
replic
effici
becom
transmiss
human
popul
viru
current
spread
defin
new
subtyp
reassort
viru
human
swine
avian
influenza
virus
transmiss
abil
among
human
be
studi
show
neuraminidas
na
glycoprotein
embed
viral
envelop
play
key
role
final
stage
infect
na
cleav
sialic
acid
cell
surfac
facilit
progeni
virion
releas
infect
cell
influenza
viru
defici
na
activ
viru
progeni
aggreg
surfac
infect
cell
thu
sever
impair
spread
virus
cell
therefor
na
recogn
key
target
develop
agent
influenza
viru
infect
determin
xray
crystal
structur
na
greatli
advanc
antiflu
drug
discoveri
develop
sinc
number
potent
na
inhibitor
oseltamivir
tamiflu
glaxosmithklin
biota
zanamivir
relenza
hoffman
la
roch
gilead
scienc
develop
antiflu
drug
addit
drug
resist
studi
na
earlier
influenza
virus
provid
insight
develop
antiflu
drug
although
newli
emerg
viru
seem
complet
resist
channel
inhibit
drug
oseltamivir
zanamivir
figur
still
effect
new
viru
therefor
interest
us
explor
reason
two
drug
still
effect
would
provid
valuabl
knowledg
discov
novel
potent
drug
viru
aim
analyz
sequenc
conserv
na
among
differ
influenza
virus
construct
threedimension
model
na
hereinaft
dock
two
drug
bind
site
result
reveal
one
mutat
identifi
among
residu
compris
bind
site
notic
affect
bind
strength
enzym
two
drug
comparison
therefor
oseltamivir
zanamivir
still
activ
inhibit
base
result
propos
strategi
develop
novel
potent
na
inhibitor
new
viru
analyz
sequenc
conserv
variou
genom
sequenc
neuraminidas
differ
locat
genbank
ncbi
http
www
whointcsrdiseaseswinefluen
use
multialign
result
show
put
bind
site
one
tyrosin
residu
sequenc
mutat
asparagin
sequenc
new
viru
strain
figur
indic
na
influenza
viru
extrem
conserv
viru
evolut
use
potenti
target
screen
compound
viru
construct
model
blastp
program
use
search
protein
data
bank
pdb
http
www
rcsborgpdb
identifi
homolog
protein
na
retriev
among
aiv
neuraminidas
complex
oseltamivir
pdb
entri
show
highest
sequenc
ident
therefor
crystal
structur
use
templat
model
structur
base
sequenc
align
figur
structur
model
use
homolog
modul
insightii
softwar
accelri
inc
san
diego
ca
usa
next
oseltamivir
zanamivir
dock
bind
site
use
autodock
program
final
model
structur
two
complex
two
drug
optim
use
amber
simul
packag
forc
field
complex
structur
respect
solvat
use
box
water
molecul
extend
least
away
boundari
protein
atom
optim
structur
subject
studi
interact
drug
enzym
result
shown
figur
sequenc
align
structur
superposit
reveal
drugbind
site
almost
ident
one
residu
mutat
rootmeansquar
deviat
model
crystal
structur
heavi
atom
line
bind
pocket
figur
result
indic
residu
compris
bind
pocket
pocket
shape
conserv
crucial
interact
oseltamivir
zanamivir
retain
model
two
drug
although
mutat
abolish
hydrogen
bond
hbond
carboxyl
group
two
drug
enzym
carboxyl
group
two
drug
form
stronger
hbond
figur
thu
bind
affin
two
drug
reduc
comparison
indic
predict
bind
affin
autodock
k
valu
figur
take
togeth
bind
mode
bind
affin
provid
possibl
explan
oseltamivir
zanamivir
use
treat
patient
infect
viru
along
fast
spread
viru
infect
peopl
treat
oseltamivir
zanamivir
inevit
viru
evolv
resist
two
drug
predict
possibl
mutat
site
respons
drug
resist
import
issu
combat
new
viru
discov
new
antiviru
drug
accord
model
structur
possibl
mutat
site
form
strong
hbond
oseltamivir
zanamivir
predict
agreement
recent
find
mutat
correspond
repres
princip
oseltamivirresist
mutant
bind
mode
also
reveal
possibl
mutat
site
may
gener
oseltamivir
andor
zanamivir
resist
effect
oseltamivir
zanamivir
bind
mode
two
drug
indic
enzym
prefer
target
task
discov
new
drug
current
emerg
situat
viru
spread
especi
case
second
cycl
viru
breakout
molecular
model
virtual
screen
method
play
import
role
task
appreci
strategi
identifi
drug
candid
exist
drug
accord
model
use
virtual
screen
eg
molecular
dockingand
pharmacophorebas
databas
search
conjunct
bioassay
strategi
use
success
discov
antisar
sever
acut
respiratori
syndrom
compound
cinanserin
modifi
structur
oseltamivir
zanamivir
target
structur
possibl
mutant
routin
fleetli
discov
new
drug
